Cargando…

Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family

[Image: see text] We describe the development and testing of ab initio derived, AMBER ff03 compatible charge parameters for a large library of 147 noncanonical amino acids including β- and N-methylated amino acids for use in applications such as protein structure prediction and de novo protein desig...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoury, George A., Smadbeck, James, Tamamis, Phanourios, Vandris, Andrew C., Kieslich, Chris A., Floudas, Christodoulos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277759/
https://www.ncbi.nlm.nih.gov/pubmed/24932669
http://dx.doi.org/10.1021/sb400168u
_version_ 1782350428405497856
author Khoury, George A.
Smadbeck, James
Tamamis, Phanourios
Vandris, Andrew C.
Kieslich, Chris A.
Floudas, Christodoulos A.
author_facet Khoury, George A.
Smadbeck, James
Tamamis, Phanourios
Vandris, Andrew C.
Kieslich, Chris A.
Floudas, Christodoulos A.
author_sort Khoury, George A.
collection PubMed
description [Image: see text] We describe the development and testing of ab initio derived, AMBER ff03 compatible charge parameters for a large library of 147 noncanonical amino acids including β- and N-methylated amino acids for use in applications such as protein structure prediction and de novo protein design. The charge parameter derivation was performed using the RESP fitting approach. Studies were performed assessing the suitability of the derived charge parameters in discriminating the activity/inactivity between 63 analogs of the complement inhibitor Compstatin on the basis of previously published experimental IC(50) data and a screening procedure involving short simulations and binding free energy calculations. We found that both the approximate binding affinity (K*) and the binding free energy calculated through MM-GBSA are capable of discriminating between active and inactive Compstatin analogs, with MM-GBSA performing significantly better. Key interactions between the most potent Compstatin analog that contains a noncanonical amino acid are presented and compared to the most potent analog containing only natural amino acids and native Compstatin. We make the derived parameters and an associated web interface that is capable of performing modifications on proteins using Forcefield_NCAA and outputting AMBER-ready topology and parameter files freely available for academic use at http://selene.princeton.edu/FFNCAA. The forcefield allows one to incorporate these customized amino acids into design applications with control over size, van der Waals, and electrostatic interactions.
format Online
Article
Text
id pubmed-4277759
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-42777592015-01-06 Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family Khoury, George A. Smadbeck, James Tamamis, Phanourios Vandris, Andrew C. Kieslich, Chris A. Floudas, Christodoulos A. ACS Synth Biol [Image: see text] We describe the development and testing of ab initio derived, AMBER ff03 compatible charge parameters for a large library of 147 noncanonical amino acids including β- and N-methylated amino acids for use in applications such as protein structure prediction and de novo protein design. The charge parameter derivation was performed using the RESP fitting approach. Studies were performed assessing the suitability of the derived charge parameters in discriminating the activity/inactivity between 63 analogs of the complement inhibitor Compstatin on the basis of previously published experimental IC(50) data and a screening procedure involving short simulations and binding free energy calculations. We found that both the approximate binding affinity (K*) and the binding free energy calculated through MM-GBSA are capable of discriminating between active and inactive Compstatin analogs, with MM-GBSA performing significantly better. Key interactions between the most potent Compstatin analog that contains a noncanonical amino acid are presented and compared to the most potent analog containing only natural amino acids and native Compstatin. We make the derived parameters and an associated web interface that is capable of performing modifications on proteins using Forcefield_NCAA and outputting AMBER-ready topology and parameter files freely available for academic use at http://selene.princeton.edu/FFNCAA. The forcefield allows one to incorporate these customized amino acids into design applications with control over size, van der Waals, and electrostatic interactions. American Chemical Society 2014-01-06 2014-12-19 /pmc/articles/PMC4277759/ /pubmed/24932669 http://dx.doi.org/10.1021/sb400168u Text en Copyright © 2014 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Khoury, George A.
Smadbeck, James
Tamamis, Phanourios
Vandris, Andrew C.
Kieslich, Chris A.
Floudas, Christodoulos A.
Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family
title Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family
title_full Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family
title_fullStr Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family
title_full_unstemmed Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family
title_short Forcefield_NCAA: Ab Initio Charge Parameters to Aid in the Discovery and Design of Therapeutic Proteins and Peptides with Unnatural Amino Acids and Their Application to Complement Inhibitors of the Compstatin Family
title_sort forcefield_ncaa: ab initio charge parameters to aid in the discovery and design of therapeutic proteins and peptides with unnatural amino acids and their application to complement inhibitors of the compstatin family
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4277759/
https://www.ncbi.nlm.nih.gov/pubmed/24932669
http://dx.doi.org/10.1021/sb400168u
work_keys_str_mv AT khourygeorgea forcefieldncaaabinitiochargeparameterstoaidinthediscoveryanddesignoftherapeuticproteinsandpeptideswithunnaturalaminoacidsandtheirapplicationtocomplementinhibitorsofthecompstatinfamily
AT smadbeckjames forcefieldncaaabinitiochargeparameterstoaidinthediscoveryanddesignoftherapeuticproteinsandpeptideswithunnaturalaminoacidsandtheirapplicationtocomplementinhibitorsofthecompstatinfamily
AT tamamisphanourios forcefieldncaaabinitiochargeparameterstoaidinthediscoveryanddesignoftherapeuticproteinsandpeptideswithunnaturalaminoacidsandtheirapplicationtocomplementinhibitorsofthecompstatinfamily
AT vandrisandrewc forcefieldncaaabinitiochargeparameterstoaidinthediscoveryanddesignoftherapeuticproteinsandpeptideswithunnaturalaminoacidsandtheirapplicationtocomplementinhibitorsofthecompstatinfamily
AT kieslichchrisa forcefieldncaaabinitiochargeparameterstoaidinthediscoveryanddesignoftherapeuticproteinsandpeptideswithunnaturalaminoacidsandtheirapplicationtocomplementinhibitorsofthecompstatinfamily
AT floudaschristodoulosa forcefieldncaaabinitiochargeparameterstoaidinthediscoveryanddesignoftherapeuticproteinsandpeptideswithunnaturalaminoacidsandtheirapplicationtocomplementinhibitorsofthecompstatinfamily